Another UV Meter give-away in ORS Hospital
This summer as well, ORS Hospital is taking a step closer to its new and old clients, by giving them a card that serves as a UV radiation indicator. UV Meter effectively measures the level of solar radiation, and gives You an instant information and advice on how to behave and dose Your stay in the Sun. You can easily check your eyewear for UV protection using this card, essentially check if your glasses offer you adequate UV protection. UV Meter is practical and easy to use, fits in your pocket. It’s always beside you. Cares after You and Your family
All patients that come in for a dermoscopic examination in July will get a UV Meter as a gift from ORS Hospital.
You can schedule appointments via phone or the internet.
Phones for scheduling: 011/3910112, 011/3910115, 069/3910112
ORS Hospital website in English
Dear clients, we can announce with pleasure that the ORS Hospital website is now fully operational in English language, for all of those coming from abroad who are trying to learn something more about themselves and their body, or simply ask for an opinion or advice.
Vemurafenib and BRAF Mutation testing are on the way in the UK
Vemurafenib, a selective inhibitor of mutant BRAF kinase, received marketing approval in the European Union (EU) in February 2012 for the monotherapy treatment of adult patients with BRAFV600-mutation-positive, unresectable or metastatic melanoma. Vemurafenib is the first drug available for the treatment of metastatic melanoma that is targeted towards a specific genetic mutation, BRAF, which is found in 35–66% of cutaneous melanomas.[11,12] Vemurafenib is a potent inhibitor of mutatedBRAF, but is inactive against wild-type BRAF.
In a phase III clinical trial (BRAF Inhibitor in Melanoma-3) involving 675 patients with BRAF p.V600E-positive metastatic melanoma, the overall survival at 6 months was 84% [95% confidence interval (CI) 78–89%] for vemurafenib vs. 64% (95% CI 56–73%) for dacarbazine, with a 63% relative risk reduction. Response rates were 48% (95% CI 42–55%) for vemurafenib and 5% (95% CI 3–9%) for dacarbazine, and progression-free survival was significantly prolonged with vemurafenib (median 5•3 months) compared with dacarbazine (1•6 months; hazard ratio 0•26, 95% CI 0•20–0•33; P < 0•0001). The cobas® 4800 BRAF V600 Mutation Test (Roche Molecular Systems Inc., Pleasanton, CA, U.S.A.) is a companion diagnostic developed in conjunction with vemurafenib to identify patients with BRAF V600 mutations, who may benefit from vemurafenib treatment. The test involves extraction of genomic DNA from the tumour sample and a real-time polymerase chain reaction (PCR) assay that detects both wild-type and mutant BRAF
ORS Hospital wins the Microsoft Health Users Group Innovation Award 2013
With great pleasure and pride, we can say that the Microsoft Health Users Group has awarded ORS Hospital with the Innovation in Flexible Mobile Workstyle Solutions Award, at the HIMSS event in New Orleans, as a user and nominator of skinScan, a melanoma screening app for Windows Phone, developed by TeleSkin. We would like to thank the Microsoft Health Users Group and Microsoft Serbia for the appointed attention. .